• [Perspectives] Sharing experiences and forming bonds at the Edinburgh Fringe
    Friday, October 3, 2025 from The Lancet Oncology
    Performers have many different reasons for sharing their stories at the Edinburgh Festival Fringe, the world's largest arts festival, which was held on Aug 1–25, 2025, in Edinburgh, UK. For Keith Alessi, the motivation to perform...
  • [Perspectives] Between the lines: an oncology diary no one assigned
    Friday, October 3, 2025 from The Lancet Oncology
    It was a quiet summer, and I was determined to switch off—no clinics, no case logs, just rest. One afternoon, while unpacking a forgotten tote bag, I came across the black diary I had carried through my oncology postings. I opened it...
  • [Articles] Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial
    Friday, October 3, 2025 from The Lancet Oncology
    In the IFM2017-03 trial, use of lenalidomide plus daratumumab, with dexamethasone limited to the first 2 treatment cycles, reduced the risk of progression or death compared with lenalidomide plus dexamethasone, with no additional safety...
  • [Articles] First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
    Friday, October 3, 2025 from The Lancet Oncology
    First-line ICIs with or without chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in participants with metastatic BRAFV600E-mutated NSCLC, particularly among specific subpopulations. These...
  • [Articles] Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study
    Friday, October 3, 2025 from The Lancet Oncology
    Integrating the genetic statuses of BRAF and TERTp into the AJCC system changes the original risk stages of the AJCC system and significantly improves the accuracy of its mortality risk classification for papillary thyroid cancer.
  • [Review] Health-care transitions for young people living beyond childhood and adolescent cancer: recommendations from the EU–CAYAS–NET consortium
    Friday, October 3, 2025 from The Lancet Oncology
    Childhood and adolescent cancer survivors (age at diagnosis: 0–21 years) face increased risk for long-term health complications and less favourable outcomes in terms of functioning and social participation. Moreover, they often...
  • [Review] Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
    Friday, October 3, 2025 from The Lancet Oncology
    Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological...
  • [Policy Review] Digital health and artificial intelligence innovations for oncology in sub-Saharan Africa
    Friday, October 3, 2025 from The Lancet Oncology
    Countries across Africa are experiencing the dual challenge of rising cancer burden and severe health-care workforce shortages, which threaten to overwhelm its already strained health systems. Simultaneously, advancements in digital...
  • [Personal View] Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials
    Friday, October 3, 2025 from The Lancet Oncology
    Since the reform of China's drug review and approval in 2015, it has successfully stimulated the enthusiasm of domestic pharmaceutical companies to carry out innovative drug research and development, especially in oncology. Chinese...
  • [Clinical Picture] Thoracic multiple meningiomas mimicking mesothelioma
    Friday, October 3, 2025 from The Lancet Oncology
    A 57-year-old woman visited Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University (Changsha, Hunan, China) in December, 2024, because of a 1-year history of chest and back pain. She had a...
  • [Editorial] Healing a fractured world: mRNA therapies to take centre stage?
    Friday, October 3, 2025 from The Lancet Oncology
    Roughly 5 years since the emergence of SARS-CoV-2, the post-pandemic world feels increasingly fractured, with rising inequality, distrust in governmental bodies, and disinformation. In many countries, the response to long-term recovery...
  • [Comment] More is not always more for older patients with multiple myeloma
    Friday, October 3, 2025 from The Lancet Oncology
    A growing list of contemporary phase 3 trials have shown that more drugs (quadruplet therapies) are superior to less drugs (triplet therapies) in patients with newly diagnosed multiple myeloma who are transplant eligible and in those who...
  • [Comment] Tumour genetics and thyroid cancer staging: a balancing act
    Friday, October 3, 2025 from The Lancet Oncology
    The utility of genotyping tumours to enhance prognostication and guide treatment decision making for patients with differentiated thyroid cancer has been a topic of significant investigation over the past two decades.1 Preoperatively,...
  • [Comment] Revisiting prostate cancer active surveillance candidacy
    Friday, October 3, 2025 from The Lancet Oncology
    Active surveillance is the preferred standard of care for men with low-risk prostate cancer. Active surveillance uses a combination of serial prostate-specific antigen (PSA) measurements, MRI, and prostate biopsies to monitor the...
  • [Correspondence] Toxicity assessment bias in the PACE-C trial
    Friday, October 3, 2025 from The Lancet Oncology
    The PACE-C trial reported by Alison C Tree and colleagues1 provides pivotal evidence comparing stereotactic body radiotherapy (SBRT) with moderately hypofractionated radiotherapy (MHRT) in patients with intermediate-risk or high-risk...
  • [Correspondence] Toxicity assessment bias in the PACE-C trial – Authors' reply
    Friday, October 3, 2025 from The Lancet Oncology
    We thank Lanwei Guo for their interest in the acute toxicity comparison from the PACE-C trial.1 We agree, as acknowledged in the paper, that the differential treatment length between the moderately hypofractionated radiotherapy (MHRT)...
  • [Correspondence] CONTACT-02: limited clinical benefit and a suboptimal control group
    Friday, October 3, 2025 from The Lancet Oncology
    The CONTACT-02 trial by Neeraj Agarwal and colleagues evaluated cabozantinib plus atezolizumab versus an androgen receptor pathway inhibitor (ARPI) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) following...
  • [Correspondence] CONTACT-02: limited clinical benefit and a suboptimal control group – Authors' reply
    Friday, October 3, 2025 from The Lancet Oncology
    We acknowledge the Correspondence from Dries Develtere on the CONTACT-02 trial, which raises concerns that the progression-free survival benefit of cabozantinib plus atezolizumab found in our trial was modest with no overall survival...
  • [Correspondence] Advancing patient-centred CINV care: gaps in olanzapine trial design
    Friday, October 3, 2025 from The Lancet Oncology
    We read with interest the Article by Mitsue Saito and colleagues.1 The study showed that adding 5 mg olanzapine after chemotherapy to standard anti-emetics improved control of chemotherapy-induced nausea and vomiting (CINV) while...
  • [Correspondence] Advancing patient-centred CINV care: gaps in olanzapine trial design – Authors’ reply
    Friday, October 3, 2025 from The Lancet Oncology
    We appreciate any readers’ interest and comments on our Article1 and we would like to provide a comprehensive response to the Correspondence by Man Sun and colleagues.
  • [Correspondence] Synthetic progestin use and young-onset breast cancer
    Friday, October 3, 2025 from The Lancet Oncology
    The pooled cohort analysis published in the July issue of The Lancet Oncology by Katie O’Brien and colleagues provides important new insight into the relationship between hormone therapy and breast cancer risk in younger women (aged...
  • [Correspondence] AJCC9V classification for HPV-positive oropharyngeal carcinoma
    Friday, October 3, 2025 from The Lancet Oncology
    We commend Allen S Ho and colleagues for their rigorous effort in advancing prognostic tools for human papillomavirus (HPV)-positive oropharyngeal carcinoma.1 The study's use of large-scale data to refine carcinoma staging is a valuable...
  • [Correspondence] AJCC9V classification for HPV-positive oropharyngeal carcinoma – Authors' reply
    Friday, October 3, 2025 from The Lancet Oncology
    We thank Shaokun Liu and colleagues for their thoughtful correspondence on the American Joint Committee on Cancer and Union for International Cancer Control Version 9 (AJCC9V) staging system for HPV-positive oropharyngeal carcinoma.1
  • [Correspondence] BrECADD and fertility: an ongoing concern
    Friday, October 3, 2025 from The Lancet Oncology
    We read with great interest the secondary analysis of the HD21 trial by Justin Ferdinandus and colleagues,1 which sheds light on fertility outcomes in patients with advanced-stage Hodgkin lymphoma treated with chemotherapy. Although a...
  • [Correspondence] BrECADD and fertility: an ongoing concern – Authors' reply
    Friday, October 3, 2025 from The Lancet Oncology
    We thank Virginie Barraud-Lange and colleagues for their thoughtful comments on our analysis of fertility in the HD21 trial.1 Their letter highlights important nuances in interpreting endocrine recovery, ovarian reserve, and real-world...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 629–40
    Friday, October 3, 2025 from The Lancet Oncology
    Kuemmel S, Graeser M, Schmid P, et al. Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial. Lancet Oncol 2025; 26:...
  • [Corrections] Correction to Lancet Oncol 2025; 26: 1067–80
    Friday, October 3, 2025 from The Lancet Oncology
    Hungria V, Robak P, Hus M, et al. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase...
  • [Corrections] Correction to Lancet Oncol 2025; 26: e423–35
    Friday, October 3, 2025 from The Lancet Oncology
    Concin N, Matias-Guiu X, Cibula D, et al. ESGO–ESTRO–ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Lancet Oncol 2025; 26: e423–35. In this Policy Review, several typographical, formatting,...
  • UK woman who refused cancer drugs was influenced by mother, inquest finds
    Thursday, October 2, 2025 from Cancer | The Guardian
    Paloma Shemirani, 23, died after refusing chemotherapy for non-Hodgkin lymphoma despite doctors’ concerns A woman who died after refusing chemotherapy doctors believed would have given her a strong chance of recovery was “adversely...
  • A trial of proton vs. photon radiation for breast cancer showed
    Thursday, October 2, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Photon- and proton-based radiation therapy conferred comparable health-related quality of life for people with breast cancer, according to the largest head-to-head comparison of the modalities for any malignancy. A higher percentage of...
  • A common supplement could supercharge cancer treatments
    Wednesday, October 1, 2025 from Cancer News -- ScienceDaily
    Zeaxanthin, best known for eye health, has been found to boost the tumor-killing power of T cells. Researchers showed it strengthens T-cell receptors, enhances immune signaling, and improves the effects of immunotherapy. Found naturally...
  • Sunbeds should be banned in UK, skin cancer experts say
    Wednesday, October 1, 2025 from Cancer | The Guardian
    Campaigners urge ministers to close tanning salons across country over dangers posed by UV radiation Sunbeds are so dangerous they should be banned in the UK, cancer experts and campaigners say. They have urged ministers to order the...
  • Dr. Mike: ‘Never forget the human that is at the heart of why you do what you do’
    Wednesday, October 1, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    NASHVILLE — It is a “scary time” to be a medical student amid new AI technology and distrust in health care, but such developments will never replace the impact of human interaction, Mikhail O. Varshavski, DO, said at OMED. “You don’t...
  • More than 40% of federal health workers furloughed during shutdown
    Wednesday, October 1, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The first government shutdown in almost 7 years began Wednesday after Congress was unable to come together on legislation to fund the federal government. The disagreement between Republicans and Democrats centers on health care coverage,...
  • Radiation similar to proton therapy for oropharyngeal cancer
    Wednesday, October 1, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Intensity-modulated radiation therapy did not increase the risk for feeding tube dependence for patients with oropharyngeal squamous cell carcinoma compared with proton therapy, according to results of a randomized phase 3 trial. The...
  • Adjuvant radiation reduces local recurrence for bladder cancer
    Wednesday, October 1, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Adjuvant radiotherapy could substantially reduce risk for locoregional recurrence for patients with advanced muscle-invasive bladder cancer, according to data presented at American Society for Radiation Oncology Annual Meeting. Results...
  • TikTok videos on GI health vary in accuracy
    Wednesday, October 1, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    TikTok is a major source for gastrointestinal health information, but the accuracy and reliability of this content can vary by condition and creator, according to research published in The American Journal of Gastroenterology. To better...
  • Colon cancer is on the rise among young people – and research points to one major culprit | Devi Sridhar
    Wednesday, October 1, 2025 from Cancer | The Guardian
    If smoking was the cancer villain of the 20th century, eating ultra-processed food may be its 21st-century counterpart Prof Devi Sridhar is chair of global public health at the University of Edinburgh Cancer used to be seen as part of...
  • Trump strikes deal with Pfizer to lower US drug prices
    Tuesday, September 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    President Donald J. Trump announced an agreement with Pfizer to sell its drug products to Medicaid for much lower prices, while also unveiling TrumpRx, a new direct-to-consumer drug website that will sidestep health insurance companies....
  • Radiation choice for prostate cancer must be personalized
    Tuesday, September 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to results of a randomized phase 3 trial. However, standard radiation still may offer stronger biochemical cancer...
  • Biomarker may guide hormone therapy for recurrent prostate cancer
    Tuesday, September 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    A genetic test could guide the use of hormone therapy for men with recurrent prostate cancer after surgery, according to data presented at American Society for Radiation Oncology Annual Meeting. Results of a randomized phase 2 trial...
  • Physicians ‘have not invested enough time’ to understand taxes
    Tuesday, September 30, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — As physicians increasingly find themselves working as employees rather than owners, understanding tax structures and preserving their income has grown more important, according to a speaker at the 2025 Women in Medicine Summit....
  • The hidden iron switch that makes cancer cells self-destruct
    Monday, September 29, 2025 from Cancer News -- ScienceDaily
    Scientists discovered that inhibiting the enzyme STK17B forces multiple myeloma cells into iron-driven death and makes therapies more effective. Early mouse studies show strong potential for a new treatment approach.
  • FDA removes Risk Evaluation and Mitigation Strategies program for vandetanib
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    The FDA has removed the Risk Evaluation and Mitigation Strategies program for vandetanib. Vandetanib (Caprelsa, Sanofi), a thyroid cancer medication, is an oral tyrosine kinase inhibitor that targets cell receptors involved in RET, VEGFR...
  • Visible family-friendly resources increase women resident numbers
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    CHICAGO — Orthopedic surgery residency programs with family-friendly resources listed on the program and Graduate Medical Education websites had a higher proportion of women residents, according to results presented here. “While not all...
  • ChatGPT demonstrates efficiency in clinical trial recruitment
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Multiple versions of ChatGPT demonstrated efficacy in identifying eligible patients for clinical trial recruitment, showing potential to complement manual chart reviews, according to a study published in Machine Learning: Health....
  • Diagnostic yield high with robotic-assisted bronchoscopy
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    Among patients with peripheral lung lesions, use of robotic-assisted bronchoscopy plus cone beam CT resulted in a higher diagnostic yield vs. three other bronchoscopy types, according to two studies. These studies were each presented as...
  • Ten things doctors wish their administrators would do differently
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    “It doesn’t matter whether you are pursuing success in business, sports, the arts or life in general: The bridge between wishing and accomplishing is discipline.” – Harvey Mackay “Our prime purpose in this life is to help others. And if...
  • Medical imaging radiation linked to cancer among children
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    One in 10 hematologic cancers among children and adolescents may be attributable to radiation exposure from medical imaging, according to study results. The risk increased proportionally with higher cumulative doses. “Medical imaging...
  • RFK represses report on health risks of alcohol
    Monday, September 29, 2025 from Healio.com HEMATOLOGY ONCOLOGY RSS Feed
    After a pronounced increase in heavy alcohol use and binge drinking during the COVID-19 pandemic, rates of alcohol consumption have declined precipitously, reaching a historic low of 54% this year, according to a recent Gallup poll....
  • Powered by Feed Informer